Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.
2.

The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.

Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, Wilkinson GR.

J Clin Invest. 1998 Jan 15;101(2):289-94.

3.

The antibiotic rifampicin is a nonsteroidal ligand and activator of the human glucocorticoid receptor.

Calleja C, Pascussi JM, Mani JC, Maurel P, Vilarem MJ.

Nat Med. 1998 Jan;4(1):92-6.

PMID:
9427613
4.

Itraconazole decreases renal clearance of digoxin.

Jalava KM, Partanen J, Neuvonen PJ.

Ther Drug Monit. 1997 Dec;19(6):609-13.

PMID:
9421099
5.

Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833.

Mayer U, Wagenaar E, Dorobek B, Beijnen JH, Borst P, Schinkel AH.

J Clin Invest. 1997 Nov 15;100(10):2430-6.

6.

Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine.

Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin-Ren P, Brown MB, Guo W, Rossi SJ, Benet LZ, Watkins PB.

Clin Pharmacol Ther. 1997 Sep;62(3):248-60.

7.

Expression of P-glycoprotein 170 in nasal mucosa may be increased with topical steroids.

Henriksson G, Norlander T, Zheng X, Stierna P, Westrin KM.

Am J Rhinol. 1997 Jul-Aug;11(4):317-21.

PMID:
9292183
8.

Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine.

Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DK, Borst P, Nooijen WJ, Beijnen JH, van Tellingen O.

Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):2031-5.

9.

Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier.

Terao T, Hisanaga E, Sai Y, Tamai I, Tsuji A.

J Pharm Pharmacol. 1996 Oct;48(10):1083-9.

PMID:
8953513
10.

Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein.

Mayer U, Wagenaar E, Beijnen JH, Smit JW, Meijer DK, van Asperen J, Borst P, Schinkel AH.

Br J Pharmacol. 1996 Nov;119(5):1038-44.

11.

Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin.

Fromm MF, Busse D, Kroemer HK, Eichelbaum M.

Hepatology. 1996 Oct;24(4):796-801.

PMID:
8855178
12.

Inhibition of the intestinal digoxin absorption and exsorption by quinidine.

Su SF, Huang JD.

Drug Metab Dispos. 1996 Feb;24(2):142-7.

PMID:
8742224
13.
15.

The mechanism of the verapamil-digoxin interaction in renal tubular cells (LLC-PK1).

Ito S, Woodland C, Harper PA, Koren G.

Life Sci. 1993;53(24):PL399-403.

PMID:
8246676
16.

Extrahepatic metabolism of drugs in humans.

Krishna DR, Klotz U.

Clin Pharmacokinet. 1994 Feb;26(2):144-60. Review.

PMID:
8162658
17.

Role of P-glycoprotein in renal tubular secretion of digoxin in the isolated perfused rat kidney.

Hori R, Okamura N, Aiba T, Tanigawara Y.

J Pharmacol Exp Ther. 1993 Sep;266(3):1620-5.

PMID:
8103798
18.

Digoxin-cyclosporin A interaction: modulation of the multidrug transporter P-glycoprotein in the kidney.

Okamura N, Hirai M, Tanigawara Y, Tanaka K, Yasuhara M, Ueda K, Komano T, Hori R.

J Pharmacol Exp Ther. 1993 Sep;266(3):1614-9.

PMID:
8103797
19.

Modulation of multidrug resistance gene expression by dexamethasone in cultured hepatoma cells.

Zhao JY, Ikeguchi M, Eckersberg T, Kuo MT.

Endocrinology. 1993 Aug;133(2):521-8.

PMID:
8102093
20.

Supplemental Content

Support Center